Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 13 unusual trades.
Delving into the details, we found 7% of traders were bullish, while 76% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $385,463, and 8 were calls, valued at $299,598.
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $65.0 and $200.0 for Moderna, spanning the last three months.
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 822.27 with a total volume of 1,051.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $65.0 to $200.0 over the last 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
MRNA | PUT | SWEEP | BEARISH | 11/15/24 | $11.15 | $11.1 | $11.1 | $85.00 | $152.1K | 237 | 139 |
MRNA | PUT | TRADE | BULLISH | 01/17/25 | $58.6 | $58.2 | $58.2 | $140.00 | $110.5K | 899 | 30 |
MRNA | CALL | TRADE | BEARISH | 06/20/25 | $9.45 | $9.2 | $9.2 | $110.00 | $61.6K | 220 | 67 |
MRNA | PUT | SWEEP | BEARISH | 09/20/24 | $10.35 | $10.0 | $10.35 | $90.00 | $53.8K | 2.4K | 52 |
MRNA | CALL | TRADE | BEARISH | 12/18/26 | $18.15 | $15.4 | $15.4 | $130.00 | $46.2K | 353 | 30 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Having examined the options trading patterns of Moderna, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
In the last month, 5 experts released ratings on this stock with an average target price of $126.0.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from Benzinga Pro.
Posted In: MRNA